| Faculty | Relationship Identified With: |
| Hans-Joachim Anders, M.D. | Consultant: Bayer, AstraZeneca, GSK, Novartis, Janssen; Speaker Honorarium: Lilly, Vifor, Otsuka |
| Sophia Ambruso | Consultant: AstraZeneca |
| Christos Argyropoulos MD, PhD, FASN | Consultant: Baxter Healthcare, Bayer |
| Roopen Arya | Speaker’s Bureau: Sanofi, Cardinal Health |
| Jonathan Barratt | Research Grants: Argenx, Calliditas Therapeutics, Chinook Therapeutics, Galapagos NV, GSK, Novartis, Travere Therapeutics; Medical/Scientific Advisor: Alnylam Pharmaceuticals, Argenx, Astellas Pharma, BioCryst Pharmaceuticals, Calliditas Therapeutics, Chinook Therapeutics, Dimerix, Galapagos NV, Novartis, Omeros, Travere Therapeutics, UCB, Vera Therapeutics, Visterra |
| Sheila Bermejo García | Reports honorarium for conferences, consulting fees, and advisory boards from AstraZeneca, Boehringer and Mundipharma |
| Snehal H. Bhatt, PharmD | Speaker’s Bureau: Janssen Global Services, LLC |
| Hannah Beba | Consultant and Speaker: AstraZeneca, Sanofi, Novonordisk; Sponsorship for Conference and Consultant and Speaker: BI/Lilly |
| Clara García Carro | Travel and congress fees support from AstraZeneca, Esteve, NovoNordisk, Boehringer Ingelheim Lilly, Astellas, Otsuka, Novartis, Astellas, and Baxter; Scientific lectures, advisory boards and scientific committees organized by AstraZeneca, Boehringer Ingelheim Lilly, Mundipharma, Esteve and NovoNordisk |
| Melvin Chan MD | Nothing to disclose |
| Dr. Fouad T. Chebib | Unrestricted research grant: Otsuka Pharmaceuticals; PI of ongoing clinical study: Natera |
| Daniel W. Coyne | Consultant: Otsuka/Akebia, Boehringer/Lilly, FMC-Renal Therapies Group, Travere, Unicycive, Daicho Sankyo; Speaker: Astra Zeneca Canada; Consultant, Speaker: Fresenius Kabi. |
| Claire Davies | Speaker: NovoNordisk, CMM, Astra Zeneca, CareFlow Medicines Management, Diabetes Professional Care, NAPP; Advisor: MTech Access, Roche; Author: Green Light Pharmacy |
| Tejas Desai | Nothing to disclose |
| Kevin Fernando, MD | Consultant/Advisor: AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Eli Lilly and Company; MSD Pharmaceuticals; NAPP Pharmaceuticals Limited; Novo Nordisk A/S; Sanofi Speaker’s Bureau: AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Eli Lilly and Company; MSD Pharmaceuticals; NAPP Pharmaceuticals Limited; Novo Nordisk A/S; Sanofi; Daiichi Sankyo, Amgen & Amarin |
| Ines Fonseca | Speaker, conference support: Novo Nordisk; Conference support: Lilly; Speaker: AstraZeneca |
| Dominique Guerrot, MD, PhD | Nothing to disclose |
| Dr. Ilana Halperin | Speaker, Consultant: Dexcom Canada, Sanofi; Speaker: Sanofi; Consultant: Abbott Diabetes Canada |
| Tess Harris | Nothing to disclose |
| Gerren Hobby, MD | Nothing to disclose |
| Will Herrington, MA, MBBS, MD, FRCP | Personal fellowship and institutional grant funding: Medical Research UK and Kidney Research UK. Research support: Boehringer Ingelheim and Lilly. I follow a departmental policy to decline any honoraria from the pharmaceutical or food industry. |
| Dr. Patrick Holmes MB BS, MSc, DipTher, MRCGP | Consultant: AstraZeneca, NovoNordisk, Eli Lilly, Abbot; Speaker’s Bureau: AstraZeneca, Boehringer Ingelheim, NovoNordisk, Eli Lilly; Research Grant Recipient: NovoNordisk, Roche |
| Noah Ivers, MD, CCFP, PhD | Evaluation consulting and speakers fee: Novo Nordisk; Evaluation consulting: Merck |
| Ellie Kelepouris MD | Advisor: Akebia Pharmaceuticals, Boehringer Ingleheim, Relypsa, GSK; Advisor/Author: Bayer Pharmaceuticals; Author/Section Editor: Up to Date; Advisor/Presenter: AstraZeneca. |
| Edgar V. Lerma | Speaker’s Bureau: AstraZeneca; Bayer; Otsuka Consultant: Vifor; Otsuka; Bayer |
| Hector Madariaga | Nothing to disclose |
| Ahmad Masri | Research Grants: Pfizer, Akcea, Ionis, Ultromics; Honoraria: Pfizer, Alnylam, Eidos, Akcea, Ionis, Cytokinetics, BMS; Consultant: Attralus, Tenaya, Ionis |
| Taher Modarressi, MD | Speakers’ Bureau: AstraZeneca |
| Dr Ahmed Mohsen, MD, MSc. | Nothing to disclose |
| James Novak, MD PhD FASN FNKF FACP | Nothing to disclose |
| Ali W. Rizvi | Nothing to disclose |
| Augusto Cesar Soares dos Santos Junior | Nothing to disclose |
| Naveed Sattar | Consulting/speaker honoraria: Abbott Laboratories, Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Janssen, MSD, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics, Sanofi; Grants: AstraZeneca, Boehringer Ingelheim, Novartis, Roche Diagnostics |
| Dr Mythri Shankar | Nothing to disclose |
| Dr Sourabh Sharma | Nothing to disclose |
| Natalie Staplin, PhD | Research funding paid to institution for EMPA-KIDNEY trial: Boehringer Ingleheim; Eli Lilly and Company. Research funding paid to institution ASCEND-PLUS trial: Novo Nordisk. |
| Dr. M. Subashri | Nothing to disclose |
| Cristina Popa | Nothing to disclose |
| Pallavi Prasad | Nothing to disclose |
| Robert Provenzano, MD, FACP, FASN, FNKF | Consultant: Fibrogen, GSK; BOD/Stock: Nephroceuticals, Organic Arthritis, Vasc-Alert |
| Dr. Amar Puttanna | Speaker’s Bureau: Novo Nordisk, Lilly-Boehringer Ingelheim, Sanofi, Daiichi- Sankyo, AstraZeneca; Consulting: Sanofi |
| Sai Santhoshini Achi, MD | Nothing to disclose |
| Abdul Qader MD | Nothing to disclose |
| Catherine Quinlan | Nothing to disclose |
| Richard Pratley | Grants from Hanmi Pharmaceutical Co., Janssen; Consulting, Speak Fees from Merck; Grants, Speaker Fees and Consulting Fees from Novo Nordisk; Consulting Fees from Pfizer; Grants from Poxel SA; Grants and Consulting Fees from Sanofi; Consulting Fees From Scohia Pharma Inc.; Consulting Fees From Sun Pharmaceutical Industries (All honoraria directed toward a non-profit which supports education and research.) |
| Brian Rifkin, MD | Nothing to disclose |
| Jade Teakell, MD | Nothing to disclose |
| Carlo Nemesio Trinidad, MD, FPCP, FPSN | Speaker: AstraZeneca; Corbridge Philippines; Otsuka; Sanofi |
| Didem Turgut MD, MSc | Nothing to disclose |
| Dilushi Wijayaratne | Nothing to disclose |
All relevant financial relationships with ineligible companies for this educational content have been mitigated.